FDA Tells Wockhardt To Assess Drug Facilities
U.S. regulators who found shortcomings with Indian drugmaker Wockhardt Ltd.'s corrective measures to address purported manufacturing standard violations at two major facilities asked the embattled generics giant to outline plans to...To view the full article, register now.
Already a subscriber? Click here to view full article